Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases of the gastrointestinal system. Approximately 20% of new diagnoses are pediatric patients. Treatment for pediatric IBD has changed in recent years, focusing on decreased steroid use, and shifting to early initiation of biologics, especially in those at risk for complicated disease. Infliximab (IFX) is used for induction and maintenance. Clinical trials have shown that IFX improves clinical remission rates, and decreases hospitalizations and surgery rates.